

Sergey Tereshchenko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028618/publications.pdf>

Version: 2024-02-01

65
papers

7,288
citations

331670

21
h-index

85541

71
g-index

87
all docs

87
docs citations

87
times ranked

7762
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	27.0	4,108
2	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
3	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.4	340
4	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
5	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	2.2	222
6	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
7	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
8	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	1.6	145
9	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
10	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	2.5	118
11	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	1.9	92
12	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
13	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	2.2	74
14	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	3.9	56
15	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
16	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	2.7	45
17	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
18	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	1.9	30

#	ARTICLE	IF	CITATIONS
19	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
20	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	6.1	26
21	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
22	Stroke prevention in patients from Latin American countries with nonvalvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	1.8	16
23	Pathological Remodeling of the Myocardium in Chronic Heart Failure: Role of PGC-1 β . <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 794-797.	0.8	14
24	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13
25	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	6.1	12
26	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. <i>Rational Pharmacotherapy in Cardiology</i> , 2015, 11, 577-581.	0.8	10
27	ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19) Tj ETQq1 1 0.784314 rgBT /Overl with COVID-19 on the prognosis. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 32-47.	0.8	10
28	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). <i>Terapevticheskii Arkhiv</i> , 2022, 94, 584-595.	0.8	9
29	The use of optimal partitionings for multiparameter data analysis in clinical trials. <i>Mathematical Biology and Bioinformatics</i> , 2016, 11, 46-63.	0.6	8
30	Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-14.	1.1	7
31	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1491-1497.	0.8	6
32	PATHOPHYSIOLOGY OF ACUTE HEART FAILURE. WHAT'S NEW?. <i>Russian Journal of Cardiology</i> , 2016, , 52-64.	1.4	5
33	Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion. <i>Russian Journal of Cardiology</i> , 2020, 25, 103-110.	1.4	5
34	Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 67-73.	0.8	5
35	The polymorphisms G(\sim 174)C in IL6 gene and G(\sim 1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. <i>Molecular Biology</i> , 2010, 44, 741-747.	1.3	4
36	NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 94-100.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	1.4	3
38	BYHEART observational trial of assessing exogenous phosphocreatine influence on the quality of life in patients with congestive heart failure. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2020, 13, 168.	0.3	3
39	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT) Tj ETQq1 1 0.784314 rgBT /Over		
40	Long-term Antithrombotic Therapy for the Prevention of Thromboembolic Complications in Patients With Chronic Heart Failure. Kardiologiya, 2014, 6_2014, 86-90.	0.7	2
41	The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Terapevticheskii Arkhiv, 2022, 94, 517-523.	0.8	2
42	Modulation of Cardiac Contractility â€“ a New Method in the Treatment of Heart Failure. Rational Pharmacotherapy in Cardiology, 2016, 12, 574-581.	0.8	1
43	IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. Rational Pharmacotherapy in Cardiology, 2018, 14, 176-183.	0.8	1
44	COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 29-33.	1.4	1
45	The Role of Markers of Organ Damage in Patients With Chronic Heart Failure. Kardiologiya, 2015, 1_2015, 70-76.	0.7	1
46	Cardiovascular pairing: modern methods of estimation, prognostic significance and possible clinical use in acute decompensation of chronic heart failure. Medical News of North Caucasus, 2015, 10, .	0.1	1
47	Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease. Kardiologiya, 2015, 2_2015, 37-41.	0.7	1
48	What We Know About Acute Decompensation of Heart Failure?. Kardiologiya, 2015, 4_2015, 91-96.	0.7	1
49	CLINICAL CASE OF USAGE OF SERELAXIN IN THE PATIENT WITH ACUTE DECOMPENSATED HEART FAILURE. Russian Journal of Cardiology, 2016, , 83-88.	1.4	1
50	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. Russian Journal of Cardiology, 2018, , 22-27.	1.4	1
51	Myocardial remodeling in patients with chronic heart failure and implanted cardiac contractility modulators. Terapevticheskii Arkhiv, 2021, 93, 1443-1450.	0.8	1
52	Chronic heart failure â€“ modification of treatment paradigm. Consilium Medicum, 2022, 24, 13-19.	0.3	1
53	SGLT2 inhibitors in acute decompensated heart failure, what do we know?. Terapevticheskii Arkhiv, 2022, 94, 565-571.	0.8	1
54	Polymorphic minisatellite eNOS4a/4b of the endothelial NO synthase gene and cardiovascular disorders. Molecular Biology, 2000, 34, 744-746.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of uric acid in patients with acute decompensated heart failure. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1066-1072.	0.8	0
56	Dynamics of Holter electrocardiogram monitoring in patients with chronic heart failure and atrial fibrillation on the background of cardiac contractility modulation. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1044-1051.	0.8	0
57	Clinico-demographic characteristics of the patients with decompensated chronic heart failure Clinico-demographic characteristics of the patients with decompensated chronic heart failure. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2011, 10, 75-80.	1.4	0
58	Effects of transluminal balloon angioplasty and stenting on the clinical course of ischemic chronic heart failure with preserved or reduced left ventricular ejection fraction: radionuclide 4D tomoventriculography data. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2012, 11, 73-78.	1.4	0
59	IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL. <i>Russian Journal of Cardiology</i> , 2016, , 80-85.	1.4	0
60	Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3â€“Years Follow-up. <i>Kardiologiya</i> , 2018, 17, 14-22.	0.7	0
61	Neutrophil gelatinase-associated lipocalin for early diagnosis of acute kidney injury in patients with acute decompensated heart failure. <i>Kardiologiya</i> , 2018, 17, 44-50.	0.7	0
62	Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. <i>Consilium Medicum</i> , 2022, 24, 28-35.	0.3	0
63	Acute decompensated heart failure. What has changed in the clinical guidelines in 2021?. <i>Consilium Medicum</i> , 2022, 24, 7-12.	0.3	0
64	Predictive value of <i>Q</i>RS<i>T</i> complex duration in patients with chronic heart failure and atrial fibrillation: retrospective study. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 503-510.	0.8	0
65	Myocardial scintigraphy with ^{99m}Tc-pyrophosphate in the diagnosis of cardiac amyloidosis: place in the diagnostic algorithm, features of the implementation and interpretation of the study. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 530-537.	0.8	0